Not yet recruitingPhase 2NCT07387198
Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab
Studying Cutaneous neuroendocrine carcinoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
- Principal Investigator
- Salah Al-Batran, Prof. Dr.Institut für Klinische Krebsforschung IKF GmbH
- Intervention
- Cemiplimab 350 mg i.v. on day 1 of every 21 days cycle for 2 cycles(drug)
- Enrollment
- 135 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2026 – 2031
Study locations (14)
- Nationales Centrum für Tumorerkrankungen, Heidelberg, Baden-Wurttemberg, Germany
- Universitätsklinikum Mannheim, Mannheim, Baden-Wurttemberg, Germany
- Universitätsklinikum Tübingen, Tübingen, Baden-Wurttemberg, Germany
- Universitätsklinikum Regensburg, Regensburg, Bavaria, Germany
- Universitätsklinikum Würzburg, Würzburg, Bavaria, Germany
- Universitätsklinikum Hamburg-Eppendorf, Hamburg, Hamburg, Germany
- Universitätsklinikum Frankfurt, Frankfurt am Main, Hesse, Germany
- Klinikum Bielefeld, Bielefeld, North Rhine-Westphalia, Germany
- Universitätsklinikum Köln, Cologne, North Rhine-Westphalia, Germany
- Universitätsklinikum Essen, Essen, North Rhine-Westphalia, Germany
- Johannes Wesling Klinikum Minden, Minden, North Rhine-Westphalia, Germany
- Universitätsmedizin Mainz, Mainz, Rhineland-Palatinate, Germany
- Universitätsklinikum Leipzig, Leipzig, Saxony, Germany
- Helios Klinikum Erfurt, Erfurt, Thuringia, Germany
Collaborators
Prof. Gutzmer, Skin Cancer Center Minden, Johannes-Wesling-Klinikum Minden, Germany · Prof. Becker, Translational Skin Cancer Research University Duisburg-Essen, Germany · Regeneron Pharmaceuticals
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07387198 on ClinicalTrials.govOther trials for Cutaneous neuroendocrine carcinoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07302347A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21)Merck Sharp & Dohme LLC
- RECRUITINGPHASE2NCT07288073TIL Therapy in cSCC and MCCKaram Khaddour, MD, MS
- RECRUITINGNCT07215988Studying Off Label Insurance Coverage for Patients With Cutaneous Cancers a "Filter" Observational StudyOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE2, PHASE3NCT06947928Placebo-Controlled Trial of IFx-Hu2.0 Followed By Pembrolizumab In Checkpoint Inhibitor Naïve Participants With Advanced Or Metastatic Merkel Cell CarcinomaTuHURA Biosciences, Inc.
- RECRUITINGPHASE1NCT06940440IFx-Hu2.0 As An Adjunctive Therapy To Pembrolizumab In Advanced Or Metastatic Merkel Cell Carcinoma (MCC)TuHURA Biosciences, Inc.
- RECRUITINGNCT06780475Validation of in Vitro Method for Anti-MCPyV Immunotherapy on Patients With Cutaneous Merkel Cell CarcinomaAssistance Publique - Hôpitaux de Paris
- RECRUITINGPHASE1NCT07080242Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine TumorsSystImmune Inc.
- RECRUITINGNCT06608511Liquid Biomarker Study in Melanoma and Non-Melanoma Skin CancersUniversity of Wisconsin, Madison